These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 2189124)

  • 41. Erythropoietin, the biology of erythropoiesis and epoetin alfa. An overview.
    Bieber E
    J Reprod Med; 2001 May; 46(5 Suppl):521-30. PubMed ID: 11396386
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin.
    Besarab A; Bolton WK; Browne JK; Egrie JC; Nissenson AR; Okamoto DM; Schwab SJ; Goodkin DA
    N Engl J Med; 1998 Aug; 339(9):584-90. PubMed ID: 9718377
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Quality of life and hematocrit level.
    Levin NW
    Am J Kidney Dis; 1992 Jul; 20(1 Suppl 1):16-20. PubMed ID: 1626552
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin.
    Eschbach JW; Kelly MR; Haley NR; Abels RI; Adamson JW
    N Engl J Med; 1989 Jul; 321(3):158-63. PubMed ID: 2747747
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A prospective open-label study evaluating the efficacy and adverse reactions of the use of Niferex-150 in ESRD patients receiving EPOGEN.
    Johnson CA; Rosowski E; Zimmerman SW
    Adv Perit Dial; 1992; 8():444-7. PubMed ID: 1361844
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Epoetin alfa. A review of its clinical efficacy in the management of anaemia associated with renal failure and chronic disease and its use in surgical patients.
    Dunn CJ; Wagstaff AJ
    Drugs Aging; 1995 Aug; 7(2):131-56. PubMed ID: 7579784
    [TBL] [Abstract][Full Text] [Related]  

  • 47. National Cooperative rHu Erythropoietin Study in patients with chronic renal failure--an interim report. The National Cooperative rHu Erythropoietin Study Group.
    Levin NW; Lazarus JM; Nissenson AR
    Am J Kidney Dis; 1993 Aug; 22(2 Suppl 1):3-12. PubMed ID: 8352269
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Management of the chronic renal failure patient receiving epoetin alfa for the treatment of anemia.
    Binkley LS
    Transplant Proc; 1991 Apr; 23(2):1831-2. PubMed ID: 2053169
    [No Abstract]   [Full Text] [Related]  

  • 49. Impact of epoetin alfa on clinical end points in patients with chronic renal failure: a meta-analysis.
    Jones M; Ibels L; Schenkel B; Zagari M
    Kidney Int; 2004 Mar; 65(3):757-67. PubMed ID: 14871396
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment of anaemia of progressive renal failure with recombinant human erythropoietin. A preliminary report.
    Salim KA; Salim S; Mathew T
    J Assoc Physicians India; 1992 Jan; 40(1):42-3. PubMed ID: 1634463
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Erythropoietin, blood viscosity and hypertension in chronic kidney failure].
    Schaefer RM; Heidland A
    Dtsch Med Wochenschr; 1989 Jun; 114(26):1046-9. PubMed ID: 2661190
    [No Abstract]   [Full Text] [Related]  

  • 52. Case management of the anemic patient. Epoetin alfa: focus on hematocrit.
    Kirlin L
    ANNA J; 1992 Feb; 19(1):66-7. PubMed ID: 1546890
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Recombinant human erythropoietin for anaemia associated with chronic renal failure in predialysis patients.
    Schaefer RM; Schaefer L; Heidland A
    Przegl Lek; 1992; 49(1-2):41-2. PubMed ID: 1455005
    [No Abstract]   [Full Text] [Related]  

  • 54. Predicting the hematopoietic response to recombinant human erythropoietin (Epoetin alfa) in the treatment of the anemia of cancer.
    Adamson JW; Ludwig H
    Oncology; 1999; 56(1):46-53. PubMed ID: 9885377
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [The recovery of erythropoiesis after the short-term Recormon treatment of renal anemia].
    Nikolaev AIu; Klepikov PV; Lashutin SV
    Ter Arkh; 1992; 64(6):90-1. PubMed ID: 1440349
    [No Abstract]   [Full Text] [Related]  

  • 56. Methoxy polyethylene glycol-epoetin beta: worth waiting for or a novelty worn off?
    Schmidt RJ
    Expert Opin Pharmacother; 2009 Jun; 10(9):1509-14. PubMed ID: 19505218
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of Epoetin alfa on hemostasis in chronic renal failure.
    Tang WW; Stead RA; Goodkin DA
    Am J Nephrol; 1998; 18(4):263-73. PubMed ID: 9653828
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Nursing care of predialysis patients receiving epoetin alfa.
    Brown JM
    ANNA J; 1991 Jun; 18(3):306-14. PubMed ID: 2064456
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Anemia treatment with erythropoietin in pregnant renal recipients.
    Cyganek A; Pietrzak B; Kociszewska-Najman B; Sanko-Resmer J; Paczek L; Wielgos M
    Transplant Proc; 2011 Oct; 43(8):2970-2. PubMed ID: 21996203
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Normalization of hematocrit in hemodialysis patients with cardiac disease does not increase blood pressure.
    Conlon PJ; Kovalik E; Schumm D; Minda S; Schwab SJ
    Ren Fail; 2000; 22(4):435-44. PubMed ID: 10901181
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.